1260141-27-2,Vonoprazan fumarate,The latest news,ANQING CHICO PHARMACEUTICAL CO., LTD.
Abstract:
Vonoprazan fumarate, known by its chemical identifier CAS 1260141-27-2, is a novel potassium-competitive acid blocker (PCAB) developed by Takeda Pharmaceutical Company. It represents a significant advancement in the treatment of acid-related gastrointestinal disorders, offering rapid and sustained acid suppression. Since its initial approval in Japan in 2014, vonoprazan has expanded its global presence, with approvals in multiple countries, including the United States in 2023.
Keywords:
Vonoprazan fumarate, CAS 1260141-27-2, TAK-438, PCAB, acid-related disorders, market analysis, generics, global sales
Introduction:
Acid-related gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers, affect millions worldwide. Traditional treatments, primarily proton pump inhibitors (PPIs), have limitations, including delayed onset of action and variable efficacy. Vonoprazan fumarate, a first-in-class PCAB, offers a promising alternative with its rapid and sustained acid suppression. This paper explores vonoprazan's journey from development to its current market status, highlighting its chemical characteristics, clinical efficacy, and commercial performance.
Chemical Properties:
Chemical Name: 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate
Synonyms: TAK-438
CAS Number: 1260141-27-2
Molecular Formula: C21H20FN3O6S
Molecular Weight: 461.46 g/mol
Solubility: Insoluble in water and ethanol; soluble in DMSO (≥18.9 mg/mL)
Storage Conditions: Store at -20°C
Development and Approvals:
Vonoprazan was developed by Takeda Pharmaceutical Company and Otsuka. It received its first approval in Japan in December 2014 for the treatment of gastric and duodenal ulcers and reflux esophagitis. Subsequent approvals include:
Russia: April 2021
United States: November 2023, approved for erosive esophagitis and later for non-erosive GERD in July 2024
Market Performance:
Since its launch, vonoprazan has shown significant market growth:
2020: $350 million
2021: $420 million
2022: $500 million
2023: $580 million
2024: $700 million
In the U.S., Phathom Pharmaceuticals reported a revenue of $7.3 million in Q2 2024, marking a 280% increase from the previous quarter. Over 122,000 prescriptions for VOQUEZNA® products were written by healthcare providers since launch, indicating strong market uptake .
Market Competition and Generics:
Vonoprazan faces competition from established PPIs. However, its rapid action and sustained efficacy provide a competitive edge. In India, companies like Sun Pharma and Cipla have entered licensing agreements with Takeda to market vonoprazan, indicating the drug's expanding global footprint . As of now, generic versions are limited, but with patent expirations approaching, increased generic competition is anticipated.
Recent Developments:
FDA approval for the treatment of non-erosive GERD in July 2024 .
Addition of VOQUEZNA® to CVS Caremark formularies, expanding access to over 116 million commercially insured patients in the U.S. .
FDA approval of reformulated vonoprazan tablets for H. pylori treatment in October 2023 .
Conclusion:
Vonoprazan fumarate represents a significant advancement in the treatment of acid-related gastrointestinal disorders. Its rapid onset, sustained efficacy, and expanding global approvals position it as a strong competitor in the market. With ongoing developments and potential generic entries, vonoprazan's market dynamics will continue to evolve, offering new opportunities and challenges in the gastrointestinal therapeutics landscape.
Active Pharmaceutical Ingredient
1260141-27-2,Vonoprazan fumarate,(chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
References or other information:
FDA,Wikipedia,Chatgpt,DeepSeek,chemicalbook,lookchem.
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
